{
  "tag": "PATIENT GUIDE",
  "title": "GLP-1 Roll-Off in Heart Patients",
  "subtitle": "A practical tapering infographic",
  "sections": [
    {
      "title": "Who this is for",
      "bullets": [
        "Stable HF patients on GLP-1 therapy",
        "No recent decompensation or ischemia"
      ]
    },
    {
      "title": "Why consider roll-off",
      "bullets": [
        "GI intolerance or weight plateau",
        "Cost, access, or coverage issues",
        "Need to reassess baseline symptoms"
      ]
    },
    {
      "title": "Taper plan (6-8 weeks)",
      "bullets": [
        "Reduce dose stepwise every 2 weeks",
        "Pause if HF symptoms worsen",
        "Keep nutrition and activity support"
      ]
    },
    {
      "title": "Monitor weekly",
      "bullets": [
        "Weight, edema, and blood pressure",
        "Dyspnea and exertional capacity",
        "Glucose trends if diabetic"
      ]
    },
    {
      "title": "Red flags",
      "bullets": [
        "Rapid weight gain or swelling",
        "Orthopnea or PND",
        "Resting HR over 110 or new arrhythmia"
      ],
      "accent": "danger"
    },
    {
      "title": "Follow-up",
      "bullets": [
        "Clinic or tele-visit at 2-4 weeks",
        "Adjust diuretics or RAASi if needed"
      ]
    }
  ],
  "callout": {
    "label": "Bottom line",
    "text": "Taper slowly, monitor symptoms, and re-titrate HF therapy if needed."
  },
  "footer": "Educational infographic. Not medical advice."
}
